ALBUQUERQUE, N.M., March 28 /PRNewswire-FirstCall/ -- Biomoda, Inc., Albuquerque, NM, http://www.biomoda.com, maker of patented early lung cancer detection testing and other cancer diagnostic technology, just received notification that it was approved by Standard & Poor’s to be carried in S&P’s Daily News and S&P’s Corporation Records.
John Cousins, President of Biomoda welcomed S&P’s approval for listing of the Company, which now for the first time, will enable investors in most of the United States to invest in Biomoda, Inc.
At the same time as the news of S&P’s approval, BIOCOM, http://www.biocom.org, the largest regional life sciences association in the world, has confirmed that Biomoda, Inc. is now included in its listings and membership.
It was previously disclosed that Mayo Clinic (Rochester, Minnesota) and Biomoda, Inc. (Albuquerque, NM) have agreed to jointly conduct a broad validation study of Biomoda’s patented technology, a non-invasive cytology based lung cancer diagnostic assay.
Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology is designed for cancer screening at an early stage of large populations at a very affordable cost.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
“Safe Harbor” Statement: This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Biomoda, Inc.
CONTACT: John Cousins of Biomoda, Inc., +1-505-821-0875